i believe in some interviews with AT, he's stated mcrpc for radiopharm could be 5b and potentially double if they can move above chemo in therapy lines.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.1070497/full
this article forecast pluvicto sales in a pretaxane and post taxane market, with a predicted 20% US penetration and 15% worldwide penetration, post taxane ~1b sales and pre taxane ~2.3b on top.
CU6 - Media and Industry News, page-378
-
- There are more pages in this discussion • 178 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.23 |
Change
0.360(5.24%) |
Mkt cap ! $2.282B | |||
| Open | High | Low | Value | Volume |
| $7.05 | $7.27 | $6.86 | $9.068M | 1.271M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2748 | $7.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.24 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |